Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|EA5181||ECOG-ACRIN||Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC||Adult CIRB - Late Phase Emphasis||Available to Open|
|GOG-0209||GOG||Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF Versus Carboplatin/Paclitaxel in Patients with Stage III & IV or Recurrent Endometrial Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1418||SWOG||A Randomized; Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/=1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy||Adult CIRB - Late Phase Emphasis||Available to Open|
|NRG-BN003||NRG||Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma||Adult CIRB - Late Phase Emphasis||Available to Open|
|NSABP-B-42||NSABP||A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|EA2161||ECOG-ACRIN||A Phase II Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET)||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1712||SWOG||A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease||Adult CIRB - Late Phase Emphasis||Available to Open|
|CALGB-80203||CALGB||A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with and without Cetuximab (C225) for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum||Adult CIRB - Late Phase Emphasis||Available to Open|
|N0147||NCCTG||A Randomized Phase III Trial of Oxaliplatin (OXAL) plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|NRG-LU002||NRG||Maintenance Systemic Therapy versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial||Adult CIRB - Late Phase Emphasis||Available to Open|